Previous Close | 44.37 |
Open | 44.64 |
Bid | 44.50 x 1100 |
Ask | 45.00 x 4000 |
Day's Range | 44.40 - 44.90 |
52 Week Range | 37.80 - 46.97 |
Volume | |
Avg. Volume | 5,160,391 |
Market Cap | 113.652B |
Beta (5Y Monthly) | 0.37 |
PE Ratio (TTM) | 18.07 |
EPS (TTM) | 2.47 |
Earnings Date | Feb 01, 2017 - Feb 06, 2017 |
Forward Dividend & Yield | 1.99 (4.48%) |
Ex-Dividend Date | May 19, 2022 |
1y Target Est | 49.81 |
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
The British drugmaker recently announced that it agreed to acquire a late-stage biopharmaceutical company.
Pharmaceutical giant GlaxoSmithKline (NYSE: GSK) missed out on this early action and now looks to launch several pandemic products this year. GSK has three separate COVID vaccines in late-stage development, in various partnerships with Sanofi (NASDAQ: SNY), South Korean pharmaceutical SK bioscience, and Canadian biopharmaceutical Medicago. GSK's Phase 3 clinical trials are wrapping up, and GSK expects regulatory decisions in the US and EU starting later this year.